A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
Condition: Idiopathic Inflammatory Myositis Interventions: Drug: Daxdilimab; Drug: Placebo Sponsor: Horizon Therapeutics Ireland DAC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials